User:Mr. Ibrahem/Tasimelteon
From Wikipedia, the free encyclopedia
Tasimelteon, sold under the brand name Hetlioz among others, is a medication used to treat non-24-hour sleep–wake disorder.[1] It is taken by mouth, an hour before bedtime.[1][3] Benefits may take months to occur.[1]
Quick Facts Clinical data, Trade names ...
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Hetlioz, Hetlioz LQ |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615004 |
License data |
|
Dependence liability | None[1] |
Addiction liability | None[1] |
Routes of administration | By mouth |
Drug class | Melatonin receptor agonist[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | not determined in humans[2] |
Protein binding | 89–90% |
Metabolism | extensive liver, primarily CYP1A2 and CYP3A4-mediated |
Elimination half-life | 0.9–1.7 h / 0.8–5.9 h (terminal) |
Excretion | 80% in urine, 4% in feces |
Identifiers | |
| |
Chemical and physical data | |
Formula | C15H19NO2 |
Molar mass | 245.322 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Close
Common side effects include headache, sleepiness, nausea, and dizziness.[3] Safety in pregnancy is unclear.[1] It works by activating the melatonin receptor.[3]
Tasimelteon was approved for medical use in the United States in 2014 and Europe in 2015.[1][3] In the United States it costs about 23,000 USD per month as of 2021.[4] Despite being approved in Europe and available in Germany it is not sold in the United Kingdom as of 2021.[5]